Company Filing History:
1 out of 2 
1 out of 7 Years Active: 2024
Title: Rafael Sanchez Sanchez: Innovator in Predicting Cardiotoxicity Risk
Introduction
Rafael Sanchez Sanchez is a notable inventor based in Valencia, Spain. He has made significant contributions to the field of medical research, particularly in predicting cardiotoxicity risk in cancer patients undergoing anthracyclines chemotherapy. His innovative approach has the potential to improve patient outcomes and enhance treatment safety.
Latest Patents
Rafael Sanchez Sanchez holds a patent for a groundbreaking invention titled "Predicting cardiotoxicity risk in cancer patients receiving anthracyclines chemotherapy." This invention refers to an in vitro method for predicting cardiotoxicity risk based on the expression levels of a combination of 10 circulating miRNAs. These miRNAs include miRNA 16-5p, miRNA 22-3p, miRNA 30b-5p/30c-5p, miRNA 92b-3p, miRNA 148a-3p, miRNA-150-5p, miRNA-192-5p, miRNA 215-5p, miRNA 486-3p/486-5p, and miRNA-4732-3p. The invention also identifies this set of miRNAs as biomarkers for predicting cardiotoxicity risk in patients receiving anthracyclines chemotherapy. Furthermore, it contemplates a method for preventing cardiotoxicity by modulating the expression levels of these circulating miRNAs.
Career Highlights
Throughout his career, Rafael has worked with esteemed institutions such as Fundación Para La Investigación Del Hospital Universitario La Fe De La Comunidad Valenciana and Maastricht University. His work has focused on advancing medical research and improving treatment protocols for cancer patients.
Collaborations
Rafael has collaborated with notable colleagues, including David Hervàs Marin and Ana Santaballa Beltràn. These partnerships have contributed to the development and validation of his innovative research.
Conclusion
Rafael Sanchez Sanchez is a pioneering inventor whose work in predicting cardiotoxicity risk represents a significant advancement in cancer treatment. His contributions have the potential to save lives and improve the quality of care for patients undergoing chemotherapy.